Literature DB >> 19288008

The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells.

Hao Hu1, Hui Ying Han, Yu Liang Wang, Xiao Peng Zhang, Chee Wai Chua, Y C Wong, Xiao Feng Wang, Ming Tat Ling, Ke Xin Xu.   

Abstract

Recurrence and progression are the major problems in the treatment of bladder cancer. Increased expression of Id-1, a basic helix-loop-helix transcription factor, has recently been shown in several types of advanced cancer. Some studies have provided evidence to suggest that Id-1 can be considered a potential therapeutic target. The objective of this study was to investigate the role of Id-1 in the chemosensitivity of bladder cancer cells, and the effect of Id-1 on chemotherapeutic drug-induced apoptosis in bladder cancer cells. We compared the different sensitivity to epirubicin in RT112 and MGH-U1 cell lines with different Id-1 expression. Then, we transfected different vectors into RT112 and MGH-U1 respectively, and generated the stable Id-1 up-regulation and down-regulation transfectants. The results of cell viability assay showed up-regulation of Id-1 in RT112 leading to increased sensitivity in response to epirubicin, and down-regulation of Id-1 increased cellular sensitivity to epirubicin. Furthermore, the analysis of apoptosis related protein revealed that up-regulation of Id-1 suppressed epirubicin-induced apoptosis and down-regulation of Id-1 leading to increased epirubicin-induced apoptosis. Wound closure assay showed up-regulation of Id-1 leading to improved migration abilities of bladder cancer cells under chemotherapy. Our results suggest that up-regulation of Id-1 in bladder cancer cells lead to increased cell viability in response to epirubicin by its improved anti-apoptotic role, and down-regulation of Id-1 increases cellular sensitivity to epirubicin by increased anticancer drug-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19288008     DOI: 10.3892/or_00000323

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  11 in total

1.  Inhibitor of DNA-binding-1/inhibitor of differentiation-1 (ID-1) is implicated in various aspects of gastric cancer cell biology.

Authors:  Wei Li; Chun-Hua Zhang; Yi-Lin Hong; Jun Li; Yong-Mei Hu; Cui-Fen Zhao
Journal:  Mol Biol Rep       Date:  2011-06-19       Impact factor: 2.316

Review 2.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

3.  Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.

Authors:  Liliana Soroceanu; Ryuichi Murase; Chandani Limbad; Eric Singer; Juanita Allison; Isabel Adrados; Rumi Kawamura; Arash Pakdel; Yayoi Fukuyo; Daniel Nguyen; Sabeena Khan; Robert Arauz; Garret L Yount; Dan H Moore; Pierre-Yves Desprez; Sean D McAllister
Journal:  Cancer Res       Date:  2012-12-13       Impact factor: 12.701

4.  Inhibitor of differentiation 1 (Id1) and Id3 proteins play different roles in TGFβ effects on cell proliferation and migration in prostate cancer cells.

Authors:  Nicole Strong; Ana C Millena; Lindsey Walker; Jaideep Chaudhary; Shafiq A Khan
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

5.  Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.

Authors:  Ryuichi Murase; Rumi Kawamura; Eric Singer; Arash Pakdel; Pranamee Sarma; Jonathon Judkins; Eiman Elwakeel; Sonali Dayal; Esther Martinez-Martinez; Mukkanti Amere; Ramesh Gujjar; Anu Mahadevan; Pierre-Yves Desprez; Sean D McAllister
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

6.  Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.

Authors:  Helena Mistry; Grace Hsieh; Sara J Buhrlage; Min Huang; Eunmi Park; Gregory D Cuny; Ilene Galinsky; Richard M Stone; Nathanael S Gray; Alan D D'Andrea; Kalindi Parmar
Journal:  Mol Cancer Ther       Date:  2013-10-15       Impact factor: 6.261

7.  LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers.

Authors:  Haiyang Yu; Xuetian Yue; Yuhan Zhao; Xiaoyan Li; Lihua Wu; Cen Zhang; Zhen Liu; Kevin Lin; Zijun Y Xu-Monette; Ken H Young; Juan Liu; Zhiyuan Shen; Zhaohui Feng; Wenwei Hu
Journal:  Nat Commun       Date:  2014-10-17       Impact factor: 14.919

Review 8.  The Id-protein family in developmental and cancer-associated pathways.

Authors:  Cornelia Roschger; Chiara Cabrele
Journal:  Cell Commun Signal       Date:  2017-01-25       Impact factor: 5.712

9.  Downregulation of CDC27 inhibits the proliferation of colorectal cancer cells via the accumulation of p21Cip1/Waf1.

Authors:  L Qiu; J Wu; C Pan; X Tan; J Lin; R Liu; S Chen; R Geng; W Huang
Journal:  Cell Death Dis       Date:  2016-01-28       Impact factor: 8.469

10.  Id Proteins Contribute to Tumor Development and Metastatic Colonization in a Model of Bladder Carcinogenesis.

Authors:  Marta Garcia-Cao; Hikmat A Al-Ahmadie; Yvette Chin; Bernard H Bochner; Robert Benezra
Journal:  Bladder Cancer       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.